Viracta Therapeutics, Inc. Quality Score
VIRX
Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Growth
Below 2%, essentially flat
FCF negative, burning cash after capex
Business Quality & Capital Allocation
Heavy dilution above 5%
Contracted >2pp, margin pressure
Positive debt with no FCF to service it
Below 8%, may not cover cost of capital
SourceQuality score computed from the 10-Q filed 11 Nov 2024, covering the period ending 30 Sept 2024, as reported to the SEC. Data last refreshed 14 Aug 2026. How this is calculated.
Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.
Peers
Pharmaceutical Preparations · Pick stocks to compare with VIRX
Spot a number that looks wrong? Check it in VIRX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing VIRX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.